When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

中性粒细胞减少性发热

最后审阅: 9 Nov 2024
最后更新: 26 Oct 2023

小结

定义

病史和体格检查

关键诊断因素

  • 近期化疗
  • 发热
完整详情

其他诊断因素

  • 年龄>65 岁
  • 免疫抑制疗法
  • 化疗所致中性粒细胞减少既往史
  • 体能状态不佳(东部肿瘤协作组织体能状态评分 [ECOG PS] >1 分)
  • 血液系统恶性肿瘤
  • 晚期疾病
  • 既往抗生素治疗方案
  • 低白蛋白(<35 g/L [<3.5 g/dL])
  • 胆红素和肝酶(天冬氨酸氨基转移酶和碱性磷酸酶)升高
  • 已有器官功能障碍和共存疾病
  • 第一轮化疗后中性粒细胞绝对计数的最低值较低(<500 cells/μl)
  • 肺炎征象(咳嗽、异常呼吸音、呼吸急促)
  • 腹痛
  • 恶心或呕吐
  • 腹泻
  • 皮肤红斑、温热、压痛
  • 黏膜炎或口腔溃疡
  • 生殖器和肛门区域的感染、炎症或溃疡
  • 留置导管感染
  • 脓尿
  • 放化疗
  • 近期病史特征和暴露
  • 鼻窦压痛
完整详情

危险因素

  • 年龄>65 岁
  • 血液系统恶性肿瘤
  • 低白蛋白(<35 g/L [<3.5 g/dL])
  • 胆红素升高
  • 肝酶升高
  • 已有器官功能障碍和共存疾病
  • 近期化疗
  • 第一轮化疗后中性粒细胞绝对计数的最低值较低(<500 cells/μl)
  • 放化疗
  • 化疗所致中性粒细胞减少既往史
  • 女性
  • 体能状态不佳(东部肿瘤协作组织体能状态评分 [ECOG PS] >1 分)
  • 晚期疾病
  • 免疫抑制疗法
完整详情

诊断性检查

首要检查

  • 全血细胞计数和分类计数
  • 尿液分析和肾功能检查(尿素和肌酐)
  • 肝功能检查 (LFTs)
  • 血培养
  • 胸部 X 线检查
完整详情

需考虑的检查

  • 胃肠道病原体分子检测
  • 尿液培养
  • 腰椎穿刺术:
  • 真菌培养和血清学检测(β-葡聚糖和半乳甘露聚糖)
  • 病毒分子检测
  • 超声心动图
  • 胸部、腹部和盆腔 CT 检查
完整详情

治疗流程

急症处理

并发症或死亡高风险:发病早期

合并症或死亡低风险:初始表现

持续性治疗

治疗 3-5 日后仍发热

撰稿人

作者

Lynne Strasfeld, MD

Associate Professor of Medicine

Department of Medicine, Division of Infectious Diseases

Oregon Health and Science University

Portland

OR

利益声明

LS declares that she has no competing interests.

鸣谢

Dr Lynne Strasfeld would like to gratefully acknowledge Dr Kenneth V. I. Rolston, Dr Lior Nesher, Dr Caron Jacobson, and Dr Joseph Antin, previous contributors to this topic.

利益声明

KVIR has research grants from Merck, Shionogi, and JMI Laboratories for the performance of in vitro studies of novel antimicrobial agents. LN has given two educational lectures sponsored by MSD. CJ and JA declare that they have no competing interests.

同行评议者

Alison Freifeld, MD

Professor of Medicine, Infectious Diseases Division

University of Nebraska College of Medicine

Omaha

NE

利益声明

AF has received payment by Merck for work as an adjudication committee member for clinical trials of letermovir. AF has received an investigator-initiated study grant from Merck.

John Wingard, MD

Price Eminent Scholar and Professor of Medicine

Director

Bone Marrow Transplant Program

Division of Hematology/Oncology

University of Florida College of Medicine

Gainesville

FL

利益声明

JW has been reimbursed by Pfizer, Merck, Astellas, and Enzon for speaking fees, fees for educational programs, and consulting.

Matthew Falagas, MD, MSc, DSc

Director

Alfa Institute of Biomedical Sciences

Marousi

Athens

Greece

利益声明

MF declares that he has no competing interests.

Ruth Pettengell, MBChB FRACP PhD

Senior Lecturer in Haematology

Honorary Consultant in Medical Oncology

St George's University of London

London

UK

利益声明

RP has received speaker fees and been reimbursed by Roche, Amgen, Chigai, and Bayer for attending several conferences. RP is a co-author of the EORTC guidelines referenced in this topic.

内容使用需遵循免责声明